- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06581146
Un estudio para comprobar la salud del hígado en niños con XLMTM, una afección muscular genética grave (EXCEL)
Un estudio epidemiológico no intervencionista de XLMTM y la expresión clínica en el hígado
XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition.
Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM.
There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study.
This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas).
In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study.
This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Astellas Gene Therapies
- Número de teléfono: 800-888-7704
- Correo electrónico: Astellas.registration@astellas.com
Ubicaciones de estudio
-
-
Ontario
-
Toronto, Ontario, Canadá
- Reclutamiento
- Site CA15001
-
-
-
-
California
-
Santa Monica, California, Estados Unidos, 90401-2072
- Reclutamiento
- UCLA Neurological Services
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Reclutamiento
- Boston Children's Hospital
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Reclutamiento
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Reclutamiento
- UPMC Children's Hospital of Pittsburgh
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Reclutamiento
- University of Utah
-
-
-
-
-
Leeds, Reino Unido
- Reclutamiento
- Site GB44006
-
London, Reino Unido
- Reclutamiento
- Site GB44003
-
Oxford, Reino Unido
- Reclutamiento
- Site GB44005
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Approximately 50 male participants < 18 years of age with genetically confirmed XLMTM will be enrolled at specialist sites.
Descripción
Inclusion Criteria:
- Participant has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene based on genetic test reports.
- Participant requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full-time mechanical ventilation, to non-invasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours)
- Participant (as applicable) and/or parent(s)/carer is willing to comply with the recommended schedule of assessments.
Exclusion Criteria:
- Participant is currently enrolled in an interventional study designed to treat XLMTM.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Participants with XLMTM
Pediatric and adolescent participants with XLMTM. |
No investigational drug will be administered to participants in this study. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence rate of cholestasis
Periodo de tiempo: Up to Week 48
|
Calculated as the number of new cases of cholestasis over 48 weeks divided by total duration of follow-up for enrolled participants. |
Up to Week 48
|
|
Point prevalence of cholestasis
Periodo de tiempo: Day 1
|
Point prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis prior to Day 1 (baseline). |
Day 1
|
|
Prevalence of cholestasis
Periodo de tiempo: Up to 1 year
|
Prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis within 1 year of Day 1 (baseline). |
Up to 1 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Genetic variants of MTM1
Periodo de tiempo: Up to Week 48
|
The association between genetic variants of MTM1 and cholestasis will be evaluated. |
Up to Week 48
|
|
Risk of cholestasis temporarily associated with environmental modifiers
Periodo de tiempo: Up to Week 48
|
Medication use, immunization history, infectious disease history and dietary habits will be collected. |
Up to Week 48
|
|
Hospitalizations
Periodo de tiempo: Up to Week 48
|
Frequency and reason for hospitalizations will be collected. |
Up to Week 48
|
|
Duration of Hospitalizations
Periodo de tiempo: Up to Week 48
|
Duration of hospitalization visits will be collected. |
Up to Week 48
|
|
Emergency room visits
Periodo de tiempo: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Hepatology specialist visits
Periodo de tiempo: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Scheduled/unscheduled office visits
Periodo de tiempo: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Non-study-specified home healthcare visits
Periodo de tiempo: Up to Week 48
|
Frequency and reason for visit will be collected. |
Up to Week 48
|
|
Surgeries/procedures
Periodo de tiempo: Up to Week 48
|
Frequency and type will be collected. |
Up to Week 48
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Medical Director, Astellas Gene Therapies
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 1600-MA-3536
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .